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bstract
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related
ortality and morbidity. Over the last 10 years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many
xtra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and
athogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines
hat may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and
pidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the
onventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2
iabetes.
 2016 Elsevier Masson SAS. All rights reserved.
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A.  Introduction
Non-alcoholic fatty liver disease (NAFLD) encompasses a
pectrum of liver pathology including simple steatosis, non-
lcoholic steatohepatitis (NASH) with varying amounts of
brosis and cirrhosis [1]. NAFLD has emerged as a public health
roblem of epidemic proportions in many parts of the world
affecting up to 30% of the adult population in the United States
nd Europe) [1,2]. The prevalence of NAFLD is much higher
n patients with type 2 diabetes (ranging from approximately 50
o 75%). Notably, patients with type 2 diabetes and NAFLD are
lso more likely to develop the more severe forms of NAFLD,
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262-3636/© 2016 Elsevier Masson SAS. All rights reserved.uch as NASH, advanced fibrosis, cirrhosis, and in some cases
epatocellular carcinoma [1,2].
Over the past decade, it has become increasingly clear
hat NAFLD is not only associated with an increased risk of
iver-related morbidity or mortality, but also it is a multisystem
isease that affects a variety of extra-hepatic organ systems, and
nteracts with the regulation of multiple metabolic pathways
3]. Strong evidence indicates that cardiovascular disease is
he leading cause of mortality in patients with NAFLD [3,4].
s detailed below, there is now also convincing evidence
uggesting that NAFLD may often precede the development of
ype 2 diabetes. This supports the assertion that the conventional
aradigm of NAFLD representing the simple “hepatic manifes-
ation” of the metabolic syndrome is outdated, and that NAFLDight be regarded as an early predictor and determinant for
he development of diabetes and other clinical traits of the
etabolic syndrome [5]. This finding may have potentially
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elevant clinical implications for the diagnosis, prevention and
reatment of type 2 diabetes.
Specifically, in this narrative review we discuss the rapidly
xpanding body of clinical evidence that supports a strong
ssociation between NAFLD and the risk of new-onset type
 diabetes, and the putative biological mechanisms underlying
his association. We also briefly discuss some of the treatment
ptions for NAFLD that may influence the risk of diabetes.
To this end, although this is not a formal systematic review,
e extensively searched PubMed database to identify relevant
rticles published up to January 2016, using the keywords “non-
lcoholic fatty liver disease” or “fatty liver” combined with
incident type 2 diabetes” or “diabetes risk”.
.  Epidemiological  evidence  linking  NAFLD  to  the  risk
f new-onset  type  2  diabetes
In this review, we have not discussed the large number of
rospective, population-based studies that used serum levels of
iver enzymes (or other surrogate markers of NAFLD such as the
atty liver index) to diagnose NAFLD. These studies have consis-
ently shown that mildly elevated serum liver enzymes (mainly
erum gamma-glutamyltransferase) are independent, long-term
redictors of new-onset type 2 diabetes in various ethnic popu-
ations (Asian, American and European people) [6–8].
Data from observational cohort (prospective or retrospective)
r case-control studies that used non-invasive imaging tech-
iques (predominantly ultrasonography that has high sensitivity
nd specificity for detecting moderate and severe steatosis) to
iagnose NAFLD are summarized in Table 1. There are now
bout 20 observational studies that have assessed the associa-
ion between NAFLD and the risk of new-onset type 2 diabetes
9–25].
The main characteristics of the study populations, the length
f follow-up period, the diagnostic criteria for diabetes, the rel-
tive risks of developing diabetes and the covariates included in
ultivariate regression models have been specified in the table.
Amongst these published studies, nearly all (except for the
tudy by Okamoto et al. [9]) have shown that NAFLD was asso-
iated with a substantially increased risk of new-onset type 2
iabetes. The risk of diabetes among these published studies
aried markedly from a 33% increase [14] to a 5.5 fold increase
n risk [11]. This wide interstudy variation in risk might reflect
ifferences in NAFLD severity, since the study by Park et al. [15]
howed that the 5-year incidence rate of type 2 diabetes increased
rogressively according to the ultrasonographic severity of
AFLD at baseline (normal: 7.0%, mild: 9.8%, moderate-to-
evere: 17.8%) in a cohort of 25,232 South Korean non-diabetic
iddle-aged men. Even after adjusting for multiple confound-
ng variables, the hazard ratios (HRs) for diabetes development
ere higher in the mild-NAFLD group (adjusted-HR 1.09; 95%
onfidence interval [CI] 0.81–1.48) and in the moderate-to-
evere-NAFLD group (adjusted-HR 1.73; 95% CI 1.00–3.01)
ompared with the no-NAFLD group, respectively. In addition,
his wide interstudy variability in NAFLD-associated risk of type
 diabetes might also reflect differences in the demographic char-
cteristics of the study populations, in the length of follow-up
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ranging from a mean period of 3 to 12.8 years) and in the varying
egree of confounder adjustment in individual studies (Table 1).
Using data from an occupational cohort study of over
2,000 South Korean individuals with measurements of insulin
esistance (by homeostasis model assessment [HOMA-IR]),
verweight/obesity and NAFLD (as detected by ultrasonogra-
hy) at baseline, Sung et al. [16] have compared the effect of
hese three risk factors (singly or in combination) on the risk of
ew-onset diabetes at 5-year follow-up. These data showed that
ach of these three risk factors was associated with an approx-
mate doubling of the diabetes risk even after adjustment for
ther established risk factors (for example, with an adjusted
dds ratio [OR] of 2.42, 95% CI 1.74–3.36, for NAFLD). When
ll three risk factors occurred together in the same individual
and this occurred in approximately 50% of patients with inci-
ent diabetes at follow-up), there was an approximately 14-fold
ncrease in diabetes risk after adjusting for potential confounding
ariables [16].
Notably, and most interestingly, in the same observational
ohort of Korean individuals, the authors have further assessed
he risk of new-onset type 2 diabetes at 5 years of follow-up in
he following three subgroups:
 in subjects in whom there was resolution of fatty liver over
5 years, i.e., fatty liver that had been present at baseline was
not present at follow-up examination;
 in subjects in whom there was a development of new fatty
liver between baseline and the follow-up examinations;
 in subjects in whom there was an increase in severity of fatty
liver status, from mild fatty liver noted at baseline to moderate-
severe fatty liver, identified at follow-up examination [20].
Interestingly, these data showed that changing fatty liver sta-
us over a 5-year period was associated with markedly different
isks of incident type 2 diabetes. In particular, as also shown in
ig. 1, there was a significant diabetes risk reduction in those
ubjects in whom fatty liver on ultrasonography resolved over
ime. In particular, in those subjects, risk of incident diabetes
ecreased to the background risk of someone who had never
ad fatty liver. Conversely, the subjects in whom the severity of
atty liver worsened over 5 years (from mild to moderate-severe)
howed a marked increase in risk of incident diabetes compared
ith the risk in people with resolution of fatty liver, supporting
he notion that more severe forms of NAFLD are associated with
igher risk of incident diabetes [20]. Similarly, Yamazaki et al.
21] recently assessed the relationship between improvement of
AFLD and risk of incident type 2 diabetes in a retrospective
ohort of 4604 non-diabetic Japanese individuals followed-up
or a period of 10 years. They found that NAFLD at baseline was
ssociated with an approximately 2.5-fold increased risk of inci-
ent diabetes, and that NAFLD improvement was significantly
ssociated with a 70% risk reduction of developing diabetes over
ime, even after adjusting for age, sex, family history of diabetes,
MI, impaired fasting glycaemia, dyslipidemia, hypertension,
nd physical exercise [21]. However, these two latter studies
re not intervention trials that focused on treating NAFLD; so
aution is needed in interpreting these results.
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Table 1
Principal observational (retrospective/prospective or case-control) studies of the association between NAFLD and the incidence of type 2 diabetes (ordered by
publication year).
Authors, year
(ref.)
Study design, sample
size, population,
follow-up, and
NAFLD diagnostic
tool
Diagnosis of incident
diabetes
No. incident cases of
diabetes; % in
non-NAFLD vs.
NAFLD cases
Adjustments
considered
Main results
Okamoto et al.,
2003 [9]
Retrospective cohort
study
n = 840 non-diabetic
Japanese subjects;
10 years; liver
ultrasonography
Fasting glucose
≥ 7.8 mmol/l or
HbA1c ≥ 6.5% or
drug treatment
n = 82 incident cases
7.6% vs. 22.5%
Age, sex, BMI, family
history of diabetes,
fasting glucose,
HbA1c, alcohol
intake, frequency of
check-ups and
changes of BMI
during follow-up
NAFLD was associated
with incident diabetes
in univariate analysis
(OR 2.62, 95% CI
1.6–4.3). This
association disappeared
after adjusting for
confounders (aOR 1.83,
95% CI 0.9–3.5)
Fan et al., 2007
[10]
Nested case-control
study
n  = 358 Chinese
NAFLD patients and
788 no-NAFLD,
matched for age and
sex; 6 years; liver
ultrasonography
Fasting glucose
≥ 7.8 mmol/l, clinical
history or drug
treatment
n = 102 incident cases
5.2% vs. 20.3%
Age, sex, BMI NAFLD was
independently
associated with incident
diabetes (aOR 4.63,
95% CI 3.0–7.1,
P < 0.001)
Shibata et al.,
2007 [11]
Retrospective cohort
study with a nested
case-control analysis
n = 3189 male
Japanese workers with
normal glucose
tolerance, no viral
hepatitis, no alcohol;
4 years; liver
ultrasonography
Fasting glucose
≥ 7.0 mmol/l or 2-h
glucose ≥ 11.1 mmol/l
on 75 g OGTT
n = 109 incident cases
1.8% vs. 8.1%
Age and BMI (in the
whole cohort
analysis); age, BMI,
smoking, blood
pressure, physical
activity, duration of
follow-up and
prevalence of
metabolic syndrome
(in the nested
case-control analysis)
NAFLD was
independently
associated with incident
diabetes both in the
whole cohort (aHR
5.50, 95% CI 3.6–8.5)
and in the nested
case-control analysis
(aHR 4.60, 95% CI
3.0–6.9, P < 0.001)
Kim et al., 2008
[12]
Retrospective cohort
study
n = 5372 non-diabetic
South Korean
subjects, no viral
hepatitis or excessive
alcohol; 5 years; liver
ultrasonography
Fasting glucose
≥ 7.0 mmol/l, clinical
history or drug
treatment
n = 234 incident cases
2.3% vs. 8.5%
Age, sex, BMI, family
history of diabetes,
smoking, fasting
glucose,
HDL-cholesterol,
triglycerides, serum
ALT
NAFLD was
independently
associated with incident
diabetes (aHR 1.51,
95% CI 1.04–2.2,
P = 0.034).
Moderate/severe
NAFLD had higher
HRs vs. mild NAFLD.
Exclusion of drinkers
did not attenuate the
association
Yamada et al.,
2010 [13]
Retrospective cohort
study
n = 12,375
non-diabetic Japanese
subjects without
hepatic diseases and
viral hepatitis; 5 years;
liver ultrasonography
Fasting glucose
≥ 7.0 mmol/l, clinical
history or drug
treatment
n = 96 incident cases
of diabetes; 0.5% vs.
2.5%
n = 728 incident IFG
cases; 4% vs. 10%
Age, sex, BMI, family
history of diabetes,
hypertension, alcohol
intake, smoking status
NAFLD was
independently
associated with incident
IFG and/or diabetes in
both sexes (aOR 1.91,
95% CI 1.6–2.3 in men
and OR 2.15, 95% CI
1.5–3.0 in women)
Bae et al., 2011
[14]
Retrospective cohort
study
n = 7849 non-diabetic
South Korean
subjects; 5 years; liver
ultrasonography
Fasting
glucose ≥ 7.0 mmol/l
or HbA1c ≥ 6.5%,
clinical history or
drug treatment
n = 435 incident cases
3.7% vs. 9.9%
Age, sex, BMI,
triglycerides, HDL
cholesterol, systolic
blood pressure,
smoking status,
physical activity,
alcohol intake, IFG
status
NAFLD was
independently
associated with incident
diabetes (aHR 1.33,
95% CI 1.1–1.7,
P < 0.05). This
association was much
stronger in pre-existing
IFG
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Table 1 (Continued)
Authors, year
(ref.)
Study design, sample
size, population,
follow-up, and
NAFLD diagnostic
tool
Diagnosis of incident
diabetes
No. incident cases of
diabetes; % in
non-NAFLD vs.
NAFLD cases
Adjustments
considered
Main results
Park et al., 2012
[15]
Prospective cohort
study (health
check-up)
n = 25,232
non-diabetic South
Korean men, no viral
hepatitis, or excessive
alcohol; 5 years; liver
ultrasonography
Fasting glucose
≥ 7.0 mmol/l, HbA1c
≥ 6.5%, clinical
history
n = 2108 incident
cases
7% in no-steatosis vs.
9.8% in mild steatosis
vs. 17.8% in
moderate-severe
steatosis
Age, waist
circumference, HDL
cholesterol,
triglycerides, systolic
blood pressure,
C-reactive protein,
HOMA-IR, serum
creatinine, family
history of diabetes,
physical exercise,
metabolic syndrome
NAFLD was
independently
associated with incident
diabetes; the HRs (95%
CI) were increased in
mild steatosis (1.09;
0.8–1.5) and in
moderate/severe
steatosis (1.73; 1.0–3.0)
vs. no-steatosis
Sung et al., 2012
[16]
Retrospective cohort
study
n = 12,853
non-diabetic South
Korean subjects;
5 years; liver
ultrasonography
Fasting glucose
≥ 7.0 mmol/l, clinical
history or drug
treatment
n = 223 incident cases
0.8% vs. 4.3%
Age, sex, BMI,
educational status,
smoking, physical
activity, alcohol
intake, HOMA-IR,
serum triglycerides,
serum ALT
The clustering of
increased HOMA-IR,
overweight/obesity, and
NAFLD markedly
increases the odds of
developing diabetes,
with effects
independent of each
other and of
confounding factors.
NAFLD was associated
with incident diabetes
(aOR 2.42, 95% CI
1.7–3.4, P < 0.001)
Kasturiratne et al.,
2013 [17]
Retrospective cohort
study
n = 2276 non-diabetic
Sri Lankan
individuals, no viral
hepatitis or excessive
alcohol consumption;
3 years; liver
ultrasonography
Fasting glucose
≥ 7.0 mmol/l, clinical
history or drug
treatment
n = 242 incident cases
10.5% vs. 19.7%
Age, sex, family
history of diabetes,
BMI, waist
circumference,
hypertension,
dyslipidemia, IFG
status, serum ALT
NAFLD was
independently
associated with incident
diabetes (aHR 1.64,
95% CI 1.2–2.2).
NAFLD was the only
predictor of incident
diabetes in those with
IFG at baseline
Chang et al., 2013
[18]
Prospective cohort
study (health
check-up)
n = 38,291
non-diabetic South
Korean subjects, no
known liver diseases,
viral hepatitis or
excessive alcohol;
5 years; liver
ultrasonography
Fasting
glucose ≥ 7.0 mmol/l,
HbA1c ≥ 6.5%, or
drug treatment
n = 2025 incident
cases
3.5% in no-NAFLD
vs. 7.4% in NAFLD
with low fibrosis score
(NFS) vs. 15.3% in
NAFLD with
intermediate/high
NFS
Age, sex, smoking
status, alcohol intake,
regular exercise,
family history of
diabetes, cholesterol,
triglycerides, HDL
cholesterol,
HOMA-IR, C-reactive
protein
The aHRs (95% CI) for
incident diabetes in
NAFLD with low NFS
and NAFLD with
intermediate or high
NFS vs. no NAFLD
were 2.0 (1.8–2.2) and
4.74 (3.7–6.1),
respectively. This
association remained
significant in subjects
with fasting
glucose < 100 mg/dL
and with HbA1c < 5.8%
Choi et al., 2013
[19]
Retrospective cohort
study
n = 7849 non-diabetic
South Korean
subjects, no viral
hepatitis or excessive
alcohol; 4 years; liver
ultrasonography
Fasting
glucose ≥ 7.0 mmol/l,
HbA1c ≥ 6.5%, or
drug treatment
n = 435 incident cases
3.5% in controls vs.
4.6% in the increased
ALT vs. 7.3% in the
steatosis vs. 11.8% in
the combined
abnormality group
Age, sex, BMI,
systolic blood
pressure,
triglycerides, HDL
cholesterol, IFG
status, physical
activity, smoking,
alcohol consumption
The HRs (95% CI) of
incident diabetes was
stepwise increased in
the elevated ALT, the
steatosis, and the
combined abnormality
group. Subjects in the
combined abnormality
group had a
significantly increased
aHR of 1.64 (95% CI
1.3–2.1, P < 0.001)
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Table 1 (Continued)
Authors, year
(ref.)
Study design, sample
size, population,
follow-up, and
NAFLD diagnostic
tool
Diagnosis of incident
diabetes
No. incident cases of
diabetes; % in
non-NAFLD vs.
NAFLD cases
Adjustments
considered
Main results
Sung et al., 2013
[20]
Retrospective cohort
study
n = 13,218
non-diabetic South
Korean subjects;
5 years; liver
ultrasonography
Fasting glucose
≥ 7.0 mmol/l, clinical
history or drug
treatment
n = 234 incident cases
0.8% in no steatosis
vs. 3.4% in mild
steatosis vs. 12.3% in
moderate-severe
steatosis
Age, sex, BMI,
glucose, insulin,
triglycerides, HDL
cholesterol, systolic
blood pressure,
alcohol use, smoking,
physical activity,
change in BMI
between baseline and
follow-up, serum
ALT, AST, GGT
Fatty liver resolved in
828, developed in 1640,
and progressed from
mild to moderate/severe
in 324 people.
Resolution was not
associated with risk of
incident diabetes (aOR
0.95, 95% CI 0.5–1.9).
Development of new
fatty liver was
associated with incident
diabetes (aOR 2.49,
95%CI 1.5–4.1,
P < 0.001). In
individuals with
worsening fatty liver
(from mild to
moderate/severe),
diabetes risk markedly
increased (aOR 6.13,
95% CI 2.6–14.7,
P < 0.001 vs. subjects
with fatty liver
resolution)
Yamazaki et al.,
2015 [21]
Retrospective cohort
study
n = 3074 non-diabetic
Japanese subjects, no
viral hepatitis or
excessive alcohol;
11.3 years; liver
ultrasonography
Fasting
glucose ≥ 7.0 mmol/l,
HbA1c ≥ 6.5%,
clinical history or
drug treatment
n = 189 incident cases
3.1 vs. 16.1%
Age, sex, family
history of diabetes,
BMI, IFG status,
dyslipidemia,
hypertension, physical
exercise
NAFLD was
independently
associated with incident
diabetes (aOR 2.37,
95% CI 1.6–3.5,
P < 0.001). NAFLD
improvement was
associated with a
reduction of incident
diabetes (aOR 0.27,
95% CI 0.1–0.6,
P < 0.001)
Fukuda et al.,
2015 [22]
Retrospective cohort
study
n = 4629 non-diabetic
Japanese subjects, no
liver disease or
excessive alcohol;
12.8 years; liver
ultrasonography
Fasting
glucose ≥ 7.0 mmol/l,
HbA1c ≥ 6.5%, or
drug treatment
n = 351 incident cases
3.2% in
non-overweight,
no-NAFLD vs. 14.4%
in non-overweight
NAFLD vs. 8.0% in
overweight
no-NAFLD vs. 26.4%
in overweight NAFLD
Age, sex, family
history of diabetes,
alcohol intake,
smoking, regular
exercise, HbA1c
aHRs for incident
diabetes vs.
non-overweight without
NAFLD group were:
3.59 (95%CI
2.14–5.76) in the
non-overweight with
NAFLD group, 1.99
(95%CI 1.5–2.7) in the
overweight without
NAFLD group and 6.77
(95%CI 5.2–8.9) in the
overweight with
NAFLD group
Ming et al., 2015
[23]
Retrospective cohort
study
n = 508 non-diabetic
Chinese subjects, no
chronic liver diseases
or excessive alcohol;
5 years; liver
ultrasonography
Fasting
glucose ≥ 7.0 mmol/l,
2-h glucose
≥ 11.1 mmol/l on 75 g
OGTT or drug
treatment
n = 20 incident cases
2.4% vs. 10.3%
Age, sex, educational
level, smoking,
alcohol intake,
physical activity,
family history of
diabetes, BMI, blood
pressure, fasting
glucose, 2-h glucose,
triglycerides, HDL
cholesterol
NAFLD was
independently
associated with incident
diabetes (aHR 4.46,
95% CI 1.9–10.7,
P < 0.001) but not with
incident prediabetes
(aHR 1.64, 95% CI
0.97–2.8)
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Table 1 (Continued)
Authors, year
(ref.)
Study design, sample
size, population,
follow-up, and
NAFLD diagnostic
tool
Diagnosis of incident
diabetes
No. incident cases of
diabetes; % in
non-NAFLD vs.
NAFLD cases
Adjustments
considered
Main results
Li et al., 2015 [24] Retrospective cohort
study
n = 4736 non-diabetic
Chinese subjects, no
viral hepatitis or
excessive alcohol;
4 years; liver
ultrasonography
Fasting glucose
≥ 7.0 mmol/l, clinical
history or drug
treatment
n = 380 incident cases
4.1 vs. 17.4%
Age, sex, blood
pressure, lipids, ALT,
uric acid, creatinine
NAFLD was
independently
associated with incident
diabetes (aHR 3.37,
95% CI 2.4–4.3)
Shah et al., 2015
[25]
Prospective cohort
study
n = 3153 non-diabetic
individuals from the
Multi-Ethnic Study of
Atherosclerosis;
9.1 years; liver
computed tomography
Fasting glucose
≥ 7.0 mmol/l, clinical
history or drug
treatment
n = 216 incident cases Age, sex, race, family
history of diabetes,
BMI, waist
circumference,
systolic blood
pressure,
triglycerides, HDL
cholesterol, glucose,
C-reactive protein,
exercise, statin use
NAFLD (defined as 1st
quartile of hepatic
attenuation on
computed tomography)
was independently
associated with incident
diabetes (aHR 2.06,
95% CI 1.5–2.8,
P < 0.001)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; CI: confidence interval; GGT: gamma-glutamyltransferase; HDL: high-
d e; IFG
r
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p
f
t
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8
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F
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(
Aensity lipoprotein; HOMA-IR: homeostasis model assessment-insulin resistanc
atio.
To date, there are very few studies examining the association
etween histology-diagnosed NAFLD and the risk of incident
iabetes. In a cohort study of 129 Sweden adults with biopsy-
roven NAFLD and elevated serum liver enzymes, who were
ollowed for approximately 14 years, Ekstedt et al. [26] found
hat the prevalence of previously known diabetes was 8.5% at
h
b
[
ig. 1. Incident type 2 diabetes at 5-year follow-up according to changes in fatty live
ohort of 13,218 South Korean non-diabetic individuals. Change in fatty liver status o
P < 0.001 when compared with the “no steatosis” category).
dapted from Sung et al. [20].: impaired fasting glycaemia; aHR: adjusted hazard ratio; aOR: adjusted odds
aseline. Notably, at the end of the follow-up, approximately
0% of these patients developed either new-onset type 2 dia-
etes or impaired glucose tolerance. Again, patients with NASH
ad an approximately threefold higher risk of developing dia-
etes than those with simple steatosis over the follow-up period
26].
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Collectively, although there is now convincing evidence that
AFLD is associated with an increased risk of new-onset type
 diabetes [10–25], and there is emerging evidence that this risk
aries according to the severity of NAFLD (as detected either by
ltrasonography or by use of non-invasive fibrosis scoring sys-
ems) [9,12–14], further evidence is unquestionably needed in
on-Asian populations, as nearly all of the studies summarised
n Table 1 have been conducted in various Asian populations,
nd most of the evidence obtained to date has been obtained
n South Korean individuals. However, a recent analysis from
he Multi-Ethnic Study of Atherosclerosis study involving more
han 3000 United States non-diabetic individuals has confirmed
hat NAFLD as detected by computed tomography was indepen-
ently associated with a two-fold increased risk of developing
ype 2 diabetes [25]. In addition, as also reported above, sev-
ral population-based cohort studies, involving European and
merican middle-aged non-diabetic individuals, have repeat-
dly shown that moderately elevated serum liver enzymes (a
roxy of NAFLD) are strongly and independently associated
ith an increased risk of new-onset type 2 diabetes [6–8].
Another important caveat to keep in mind when examining
he results from published studies is that the adjustment for estab-
ished risk factors of diabetes and other potential confounding
actors was often incomplete. For example, data on waist circum-
erence was often lacking, whereas family history of diabetes,
nsulin resistance index values and physical activity were not
lways included in multivariate regression models. Additional
ollow-up studies with a larger panel of established and emerg-
ng diabetes risk factors (e.g., higher serum ferritin and lower
diponectin levels that have been also associated with the pres-
nce and severity of NAFLD) are needed to firmly establish an
ndependent contribution of NAFLD per se to the risk of new-
nset type 2 diabetes. Finally, it is important to underline that in
one of the published studies, except for the studies by Shibata
t al. [11] and by Ming et al. [23]; the diagnosis of diabetes was
ased on 2-hour postload plasma glucose concentrations.
.  Putative  biological  mechanisms  by  which  NAFLD
ontributes to  diabetes  development
When imbalance occurs between energy intake and energy
xpenditure, or when there is an intrinsic problem with storing
xcess energy as tri-acylglycerol in adipose tissue depots, lipid
ccumulates in other organs throughout the body. If lipid accu-
ulates in tissues or organs not designed to accumulate fat, e.g.,
iver or omentum, the term ‘ectopic fat accumulation’ infers that
ipid accumulation has occurred in a non physiological site with
he potential for increasing risk of certain common diseases such
s diabetes, CVD and NAFLD [27].
NAFLD is an example of ectopic fat accumulation in liver
nd this lipid accumulation is usually associated with: insulin resistance, abnormal substrate fluxes [28];
 increased secretion of hepatokines [29];
 increased gluconeogenesis;
t
n
r
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 decreased glycogen synthesis and inhibition of insulin
signalling pathways [30,31].
When excess hepatic lipid accumulates (NAFLD), it not only
as the potential for causing insulin resistance but there is also
he potential for chronic liver inflammation, increasing risk of
rogressive fibrotic liver disease, cirrhosis and hepatocellular
arcinoma. Such a pathological state also has the potential for
ncreasing both very low-density lipoprotein (VLDL) secre-
ion and hepatic glucose output. Marked liver fat accumulation,
ncreased VLDLs, increased hepatic glucose output and insulin
esistance are all associated with increased risk of diabetes. Fig. 2
llustrates the potential mechanisms leading to altered lipid and
lucose metabolism resulting from and contributing to insulin
esistance and increased hepatic glucose production in NAFLD.
he figure schematically illustrates some of the key mechanisms
elevant to the pathways that operate in the adipose tissue (panel
), the liver (panel B), and the intestine (panel C).
It is now clear that adipose tissue dysfunction/inflammation
s also important in NAFLD pathogenesis, and increasing evi-
ence now suggests that the intestine is also involved in the
eveloping disease process. Alteration of the normal intesti-
al microbiota (dysbiosis) also plays a key role in regulating
everal intrahepatic metabolic and inflammatory pathways that
re involved in the development of NAFLD and diabetes. For
xample, data obtained in mice illustrate the importance of the
ut microbiota for affecting hepatic lipid levels, and serum glu-
ose and insulin concentrations. Such data has shown that oral
reatment of lean germ-free mice with the caecal microbiota
rom obese mice caused an increase in hepatic triglyceride accu-
ulation, and insulin resistance with increased serum insulin
nd glucose concentrations [32]. Several different mechanisms
ave been suggested that are involved in the pathogenesis of
ysbiosis-induced NAFLD and that contribute to the develop-
ent and progression of liver disease in NAFLD. For example,
ncreased intestinal absorption of multiple bacterial products,
uch as short-chain fatty acids (e.g., butyrate, propionate and
cetate), lipopolysaccharide and endotoxins, have the poten-
ial to influence both hepatic glucose and lipid metabolism,
romote hepatic inflammation and increase gut permeability,
hus adversely influencing the risk of inflammation beyond the
iver [27,33,34]. Intestinal dysbiosis perturbs biliary cholesterol
etabolism, and altered bile acids in the intestine can modify
he gut microbiota. Bile acids are derived initially from hepatic
holesterol metabolism and are capable of acting as signalling
olecules which are capable of activating some receptors, e.g.
arnesoid X receptor (FXR), and modifying signalling path-
ays that influence both liver lipid metabolism and hepatic
lucose metabolism. Recently, there has been considerable inter-
st in this field, with the appreciated that subtle changes in
he bile acid structure can profoundly influence their efficacy
s signalling molecules. For adding an ethyl group at car-
on position 6 in chenodeoxycholic acid, it markedly affects
he ligand-binding capability of chenodeoxycholic acid to the
uclear hormone FXR. Treatment with obeticholic acid has
ecently shown promise in treating NASH in the Farnesoid X
eceptor Ligand Obeticholic Acid in NASH Treatment (FLINT)
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Fig. 2. Potential mechanisms leading to altered lipid and glucose metabolism resulting from and contributing to insulin resistance and increased hepatic glucose
production in NAFLD. Panel A: adipose tissue, panel B: liver, and panel C: intestine. (A) Adipose tissue. Synthesis of lipid intermediates from long-chain fatty acids
(LCFAs), e.g., lyso-phosphatidic acid, phosphatidic acid (PA), di-acylglycerol (DAG) and tri-acylglycerol (TAG). Synthesis of various species of DAG in particular
may promote adipose tissue inflammation. Increased production of free fatty acids (FFAs) and glycerol from hydrolysis of TAG may promote hepatic gluconeogenesis
and increase hepatic glucose output/production. (B) Liver. Synthesis of lipid intermediates from LCFAs, e.g., ceramide, lyso-phosphatidic acid, phosphatidic acid
(PA), di-acylglycerol (DAG), tri-acylglycerol (TAG) and very low-density lipoprotein (VLDL) secretion. Synthesis of various species of DAG, in particular, may
promote hepatic inflammation; and DAG and possibly ceramide and di-palmitoyl-phosphatidic acid (Di-P PA) increase hepatic insulin resistance by decreasing
efficient insulin signalling (e.g. via DAG/PKCinhibition of insulin receptor kinase activity) to decrease glycogen synthesis. (C) Intestine. Dysbiosis, perhaps caused
by alterations in diet and genetic factors, increases synthesis of secondary bile acids with consequent hepatic toll-like receptor-4 (TLR-4) activation, altered farnesoid
X receptor (FXR) activity and subsequent increased hepatic inflammation, fibrosis, increased risk of cancer and increased hepatic glucose production. In NAFLD
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and insulin resistance, dysfunction of glucagon-like peptide (GLP-1) secretion
epatic gluconeogenesis and lipogenesis.
rial with improvement in liver histology in approximately 50%
f patients with non-cirrhotic NASH [35].
.1.  Hepatic  lipid  accumulation,  insulin  resistance,  insulin
learance, adipose  tissue  lipolysis  and  hepatic  glucose
roduction
Although obesity is strongly associated with hepatic steato-
is, excess body fat accumulation is not necessarily a
p
d
s
fltered short chain fatty acid (SCFA) production may also adversely influence
equirement for developing NAFLD. People with lipodystrophy
ave marked insulin resistance and commonly develop hepatic
teatosis and type 2 diabetes, strongly suggesting that it is not
ody fat quantity per  se  that is important, but it is abnormal
dipose tissue function that is a key contributor to NAFLD
athogenesis [36]. In insulin sensitive individuals, postpran-
ial increases in insulin concentrations are very effective in
uppressing lipase activity in adipose tissue to decrease serum
ree fatty acid (FFA) concentrations and thereby decreased FFA
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uxes to the liver. In contrast, in insulin resistant individuals
here is decreased inhibition of insulin-mediated suppression
f FFA concentrations with resultant increased FFA fluxes to
he liver. Specifically, in the presence of insulin resistance,
ncreased FFA fluxes to the liver increase the availability of
ong-chain fatty acyl-CoAs for hepatic lipid metabolism. Such
n effect occurs in sedentary obese individuals, who do not ben-
fit from the ameliorating effect of increased muscle activity
nd increased mitochondrial fatty acid oxidation, which would
ormally buffer the liver from the burden of high FFA levels
33]. With the increased fluxes of long-chain fatty acyl CoAs
hrough the liver, evidence is accumulating that hepatic lipid
ccumulation is capable of promoting hepatic insulin resistance
nd hepatic inflammation through accumulation of di-acyl glyc-
rols (DAGs) and protein kinase C  (PKC-) activity, inhibiting
he insulin signalling pathway and promoting insulin resis-
ance (reviewed in detail in [28]). The conversion from TAG
o DAG is mediated by adipose triglyceride lipase (ATGL)
nd comparative Gene Identification-58 (CGI-58) is an activa-
or of ATGL. DAG activates PKC  membrane translocation to
nhibit the insulin receptor kinase and decrease insulin signalling
37].
With decreased effective insulin signalling activity in sub-
ects with insulin resistance, there is also decreased postprandial
lycogen synthesis. Increased fluxes of hepatic long-chain fatty
cyl-CoAs also promote hepatic glucose production, thereby
ncreasing the risk of glucose intolerance and diabetes. Increased
uxes of long-chain fatty acyl-CoAs effects allosteric activation
f pyruvate carboxylase-phosphoenolpyruvate carboxykinase
ctivity with resulting stimulation of hepatic gluconeogenesis
nd increased hepatic glucose output. Additionally, increased
dipose tissue tri-acylglycerol lipolysis also produces increased
evels of glycerol from the hydrolysis of more tri-acylglycerol
olecules. Once liberated from tri-acylglycerol, glycerol is not
e-esterified back into tri-acylglycerol by the adipocyte, because
he adipocyte does not possess the required glycerol kinase activ-
ty. Consequently, increased tri-acylglycerol hydrolysis results
n increased glycerol fluxes to the liver, increasing the produc-
ion of dihydroacetone phosphate, hepatic gluconeogenesis and
he production of hepatic glucose [28].
Hepatic lipid synthesis stimulated by increased fluxes of
ong-chain acyl Co-As to the liver, increases production
f other lipid intermediates, besides DAGs, such as, di-
almitoyl phosphatic acid and other lipid products, such as
eramides [38]. Many of these lipid intermediates promote
epatic inflammation [39–42] and increasing risk of progres-
ive liver disease that occurs with NASH. Hepatic lipids that
re not esterified also induce endoplasmic reticulum stress,
eading to the activation of c-Jun N-terminal kinases and
uclear factor kappa (NF-B)-light-chain-enhancer of activated
 cells [43], which are two major regulators of inflamma-
ory pathways that also inhibit phosphorylation of insulin
eceptor substrate (IRS)-1 [44], potentially further aggravating
epatic insulin resistance and increasing intrahepatic cytokine
roduction.In the liver, ceramides utilise long-chain FAs [45] and
eramides can accumulate into the cells via three main routes: sabolism 42 (2016) 142–156
 the hydrolysis of the membrane phospholipid sphingomyelin,
which is coordinated by the enzyme sphingomyelinase;
 de novo synthesis from long-chain FAs such as palmitate and
serine;
 a ‘salvage’ pathway that utilises sphingosine and forms
ceramide [46,47].
Although in the past, it was thought that ceramide was simply
 structural molecule, there is some evidence that increases in
embrane ceramide may cause insulin resistance [48], poten-
ially providing a mechanism to link hepatic lipid metabolism
nd hepatic inflammation. Recently, it has been suggested that
ifferences in ceramide metabolism may also explain why
AFLD with insulin resistance is associated with features of
he metabolic syndrome; whereas the patatin-like phospholi-
ase domain-containing protein 3 (PNPLA3  148MM) genotype,
ssociated with NAFLD, is not associated with metabolic syn-
rome (and thereby with no increased risk of type 2 diabetes)
49]. In such study, the liver lipidome was analysed from tissue
btained from liver biopsies in 125 subjects who were divided
nto similarly sized groups based on median HOMA-IR (‘high
s. low HOMA-IR’, n  = 62 and n  = 63) or PNPLA3 genotype
PNPLA3 148MM/MI, n  = 61 vs. PNPLA3  148II, n  = 64). The
esults of this small experimental study showed that for the
high HOMA-IR’ vs. ‘low HOMA-IR’ group comparison, in the
ore insulin resistant group (the high HOMA-IR group) the liver
as markedly enriched with saturated and monounsaturated tri-
cylglycerols and free fatty acids, dihydroceramides (markers
f de  novo  ceramide synthesis) and ceramides [49]. Clearly, the
esults of this study suggest that further work is needed to better
nderstand hepatic processing and remodelling of liver lipids
uch as ceramides, and how ceramides cause hepatic insulin
esistance in people with genotypes such as PNPLA3  148MM
hat is known to influence liver disease in NAFLD.
Besides increased insulin resistance in NAFLD, it is also
lausible that part of the reason for patients with type 2 diabetes
nd NAFLD often require large doses of exogenous insulin to
elp control plasma glucose concentrations, is that insulin clear-
nce may also be increased in patients with NAFLD. Recent
ata suggest that increased insulin clearance may occur in sim-
le steatosis and also in NASH [50]. These investigators studied
yperinsulinemia and its relationship to liver histology in con-
rol subjects, patients with simple steatosis and in patients with
ASH. Patients with simple steatosis and NASH had a similar
30% reduction in hepatic insulin clearance, when compared
o patients without NAFLD. Reduced hepatic insulin clearance
as not associated with severity of inflammation, ballooning,
nd fibrosis. In contrast to hepatic insulin clearance, worse histo-
ogical inflammation and ballooning (but not hepatic steatosis or
brosis) were associated with a progressive reduction in whole-
ody insulin clearance [50].
.2.  Secreted  hepatokines,  and  the  role  of  incretins  andRecently, it has been proposed that there are molecules
ecreted from the liver that are capable of adversely influencing
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Table 2
Pharmacologic treatments of NAFLD, with potential impact on glucose metabolism, tested in randomized clinical trials with histologic outcomes.
Author, year [Ref] Treatment, number of cases.
Patients with diabetes
Treatment
duration
Experimental drug effect on
liver disease at histology
Effects on glucose metabolism
and diabetes parameters
Bugianesi et al.,
2005 [72]
MET 2 g, 55; Vit. E, 28; Diet,
27. Only 10 cases with T2DM
12 months Vit. E and Diet did not
produce histological effects
and were combined as
controls. MET decreased liver
fat (P < 0.001), fibrosis and
necro-inflammation
(P = 0.012) at follow-up vs.
controls
On average MET decreased
fasting glucose by 10 mg/dL
and insulin by 4.5 mU/mL vs. a
limited decrease of only
5 mg/dL and 1.5 mU/mL in
other arms, respectively
Belfort et al., 2006
[73]
PIO 45 mg, 29; counselling, 25.
55 with IGT/T2DM
6 months PIO significantly improved
steatosis, inflammation,
ballooning and fibrosis vs.
counselling (P < 0.01 for all)
PIO decreased fasting glucose
by 20 mg/dL, A1c by 0.7% and
fasting insulin by 5 mU/mL vs.
unchanged in PL (P < 0.01)
Ratziu et al., 2008
[74]
FLIRT trial
RSG 8 mg, 32; PL, 31. 16 with
T2DM
12 months RSG improved steatosis
(P = 0.014), without
differences in fibrosis or
necro-inflammation
RSG decreased glucose by
16 mg/dL, A1c by 0.2%, insulin
by 5.5 mU/mL vs. unchanged
or increased in PL
Aithal et al., 2008
[75]
PIO 30 mg, 37; PL, 37. Cases
with T2DM were excluded
12 months PIO decreased
necro-inflammation (PIO vs.
PL, 0.005) and Mallory-Denk
bodies (P = 0.004)
High PIO decreased glucose by
7 mg/dL, A1c by 0.2% vs.
+7 mg/dL and +0.1% in PL
(P < 0.02)
Haukeland et al.,
2009 [76]
MET 2.5–3 g, 24; Controls, 24.
All cases had prediabetes or
T2DM
6 months No differences in steatosis,
necro-inflammation or fibrosis
were observed between MET
and controls
MET produced a moderate
reduction of glucose
(−5 mg/dL) and HbA1c
(−0.2%)
Shields et al.,
2009 [77]
MET 0.5–1 g 9; Counselling,
10. T2DM subjects were
excluded
12 months MET did not change NAFLD
activity score and its
individual components
Improved HOMA-IR values in
all patients, without differences
between groups
Ratziu et al., 2010
[78]
FLIRT 2 trial
RSG, 53 (RSG-RSG, 25;
PL-RSG, 28). Open-label
extension of FLIRT [72]
24 months RSG did not produce any
additional histological
improvement beyond the 1
year liver biopsy
No changes in biochemistry
were observed during the
extension period
Sanyal et al., 2010
[79]
PIVENS trial
PIO 30 mg, 87; Vit. E, 84; PL,
83. All subjects had NASH.
Patients with diabetes were
excluded
96 weeks Both drugs were better than
PL on steatosis (P < 0.001)
and lobular inflammation
(P < 0.01), not on fibrosis.
Higher rates of NASH
resolution were reported on
both experimental drugs
Improved fasting glucose levels
and HOMA-IR were observed
on PIO vs. PL
Lavine et al., 2011
[80]
TONIC trial
Paediatric study: Vit. E 800 UI,
57; MET 1 g, 57; PL, 58. No
subjects had diabetes at entry
96 weeks NAS score improved in all
groups. Higher rates of NASH
resolution were observed on
Vit E in subjects with NASH
at entry (58% vs. 28%;
P = 0.006). Only ballooning
improved on MET
No remarkable differences in
the time-courses of fasting
glucose or HOMA-IR were
reported between groups
Neuschwander-
Tetri al. 2014
[35] FLINT
trial
OCA 25 mg, 141; PL 142. Trial
stopped for superiority: OCA,
102; PL, 98. 52% with T2DM
72 weeks The study was discontinued
early for efficacy: improved
histology (steatosis, lobular
inflammation, ballooning,
fibrosis) in 45% OCA vs. 21%
PL. Definite NASH resolution,
22% vs. 13% (P = 0.08)
No changes in fasting glucose
between groups, but OCA was
associated with increased
insulin levels (P = 0.02 vs. PL)
and HOMA-IR
Armstrong et al.,
2015 [58]
LEAN program
LIRA 1.8 mg, 26; PL, 26. 33%
of cases had T2DM and were
on chronic MET (+SULFA in
4%)
48 weeks
(extension to
72 weeks)
LIRA was associated with
higher rates of improvement in
steatosis, ballooning and
fibrosis. NASH resolution
occurred in 39% of cases on
LIRA vs. 9% in PL; P = 0.02)
Weight loss, 5.3 kg on LIRA vs.
0.6 on PL (P = 0.003).
Significantly reduced glucose
(−18 mg/dL), A1c (−0.5%) vs.
PL (P = 0.005 and P = 0.03,
respectively)
A1c: glycosylated haemoglobin; HOMA-IR: homeostasis model assessment-insulin resistance; IGT: impaired glucose tolerance; LIRA: liraglutide; MET: metformin;
OCA: obeticholic acid; PIO: pioglitazone; PL: placebo; RSG: rosiglitazone; T2DM: type 2 diabetes mellitus; Vit E: vitamin E.
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lucose metabolism in NAFLD. These factors (or hepatokines)
nclude fetuin A [51], adropin [52], angiopoietin-like protein
53], fibroblast growth factor-21 [54], and selenoprotein [55]. All
f these hepatokines have been suggested as potential endocrine
ediators of insulin resistance and/or glucose intolerance in
AFLD. As such, it has been proposed that these molecules
ave the potential to adversely influence glucose tolerance in
atients with NAFLD.
Recent interest has also focussed on fetuin-B as a hepatokine
hat is capable of having an endocrine function beyond the liver
o influence adversely insulin sensitivity and cause glucose tol-
rance. A recent study of 168 hepatokines, of which 32 were
ifferentially secreted in steatotic versus non-steatotic hepato-
ytes showed that fetuin B was increased in humans with liver
teatosis and in patients with type 2 diabetes [56]. These investi-
ators then showed both in in  vitro  experiments and in mice that
etuin B impaired insulin action ex  vivo  in myotubes and in hepa-
ocytes, and also caused glucose intolerance in  vivo  in mice. As
roof of concept that fetuin B was responsible for glucose intol-
rance in  vivo, they then showed that silencing of fetuin B in the
bese mice improved glucose tolerance in these animals [56].
hus, these data strongly suggest that steatotic and inflamed
iver is able to secrete a hepatokine that is capable of having an
ndocrine function beyond the liver to influence adversely glu-
ose tolerance. It is plausible that the protein secretory profile
f hepatocytes in NAFLD is altered with developing steatosis,
nd the production of hepatokines is linked to inflammation and
nsulin resistance in NAFLD.
The regulation of glucagon secretion involves the gut hor-
one glucagon-like peptide-1 (GLP-1), and in type 2 diabetes
asting hyperglucagonaemia may contribute to increased hepatic
lucose production [57]. Although the precise role of glucagon
n NAFLD remains uncertain, NAFLD is frequently associated
ith abnormal glucose tolerance and there has been recently
onsiderable interest in the role of incretins, such as GLP-1, in
AFLD. Liraglutide is one such GLP-1 agonist that is used as
 once daily treatment for hyperglycaemia in type 2 diabetes.
lthough there is not good evidence of GLP-1 receptor expres-
ion in the human liver, the safety and efficacy of liraglutide at
 dose of 1.8 mg/day was recently tested in a small-randomised
linical trial in patients with biopsy-confirmed NASH [58], as
pecified in the section below.
.  Treatment  options  for  NAFLD  that  may  inﬂuence
isk of  type  2 diabetes
The past decade has been characterized by an intensive search
f effective treatments for NAFLD, fostered by the evidence of a
ignificant burden of disease for all national healthcare systems.
ehavioural changes, including dietary restriction and increased
hysical activity, and drug therapy are the pillars of NAFLD
reatment. The assessment of their effects on the risk of disease
rogression has been limited by several factors: the lack of valid surrogate markers, making liver biopsy
mandatory to demonstrate solid improvements;
t
O
aabolism 42 (2016) 142–156
 treatment outcomes undefined at regulatory levels. Only
recently the outcome of NASH improvement or regression,
without worsening of fibrosis, had gained general consensus
[59];
 limited treatment duration (maximum, 2 years). Nonetheless,
a significant benefit of both weight loss and drug treatment
on liver histology has been reported in recent reviews [60,61],
but only a few data are available on the risk of progression to
diabetes.
.1.  Weight  loss  and  decreased  diabetes  risk  in  NAFLD
Considering that overweight/obesity and insulin resistance
re a hallmark of NAFLD, there is no surprise that weight
oss may considerably affect diabetes risk. In most cases, the
ethodology used for promoting weight loss was the same or
as strictly derived from the classical methodology used in
he Diabetes Prevention Program [62], where a 58% reduced
isk of type 2 diabetes was measured in subjects with predia-
etes over a 4-year follow-up period [63]. In the same study,
here was a consistent decline of serum ALT levels in relation
o weight loss in the entire cohort, and weight loss was sig-
ificantly associated with a decreased risk of abnormal liver
nzymes in subjects with normal ALT levels at baseline [64]. No
ata were reported on progression to diabetes in relation to serum
LT changes, and circulating ALT levels remain a very crude
arker of NAFLD and NAFLD progression. In 1087 subjects
ith ultrasonography-detected NAFLD, randomly assigned to
 lifestyle modification intervention based on physical activity,
iet and behaviour therapy were compared with usual care on
AFLD remission [65]. Weight loss was larger in the interven-
ion group and was associated with a significant reduction of
erum liver enzymes, as well as a 30-mg/dL reduction in blood
lucose. No data were reported on risk of incident diabetes.
Unfortunately, trials of dietary or behavioural treatment of
AFLD rarely classify their population in terms of glucose
egulation as normal, prediabetes or diabetes, to verify the
ffectiveness of this treatment on diabetes risk, and the short
uration of intervention precludes any analysis. Vilar-Gomez
t al. recently reported the result of an intensive, prospective
ehavioural intervention aimed at weight loss in a 1-year follow-
p of 293 NASH patients, observed at a tertiary medical centre in
avana, Cuba [66]. The outcome measure was NASH resolution
ithout worsening of fibrosis in paired liver biopsies (available
n 261 participants). Weight loss ≥  5% was observed in 30% and
he probability to achieve NASH resolution was strictly depend-
nt on the amount of weight loss (58% in subjects with weight
oss ≥  5%; 90% with weight loss ≥  10%). Only 33% of cases
ad type 2 diabetes, with another 33% with prediabetes and
3% with normal glucose regulation [66]. Follow-up glucose
ata have not been reported, but it will be largely impossible to
emonstrate if the expected reduction of incident diabetes is due
o NASH resolution or to weight loss per  se.Many more data are available on diabetes risk in rela-
ion to bariatric surgery-induced weight loss. In the Swedish
bese Subjects intervention study, surgery produced a system-
tic reduction of incident diabetes vs. obese matched controls
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67]; the effect was directly associated with the amount of weight
oss [68], not with baseline BMI [69]. In the same cohort of
orbidly obese subjects undergoing surgery, weight loss was
ccompanied by a systematic reduction of serum liver enzymes
t 2-year and 10-year follow-up, considered surrogate markers
f steatosis, also proportional to the degree of weight loss [70].
n another recent study, follow-up biopsies in morbidly obese
atients with NASH at baseline have shown that the massive
eight loss induced by bariatric surgery was accompanied by
ASH resolution in 85% of cases, and a 10-mg/dL reduction
f blood glucose. Notably, those patients who did not achieve
ASH resolution were characterized by lower weight loss and
aintained higher values of insulin resistance [71]. In conclu-
ion, a large body of evidence suggests to date that weight loss,
ndependently of the therapeutic strategy, significantly improves
AFLD and NASH and reduces the risk of incident type 2 dia-
etes, but the independent effect of improved liver disease has
ever been demonstrated.
.2.  Drug  treatment  of  NAFLD  with  a  deﬁned  impact  on
lucose metabolism
Considering that insulin resistance is the hallmark of
AFLD, drugs acting on glucose metabolism (Table 2) have long
een considered for NAFLD treatment [35,58,72–80]. Insulin
ensitizers have been tested in several clinical trials of different
uration. They are very likely to reduce both the risk of incident
iabetes and to improve metabolic control in the NAFLD popu-
ation without and with diabetes, respectively. This therapeutic
ffect has been demonstrated with metformin, which is the basis
f diabetes treatment and significantly reduces the progression of
rediabetes to diabetes in several large intervention trials. How-
ver, initial evidence for an effect of metformin on NAFLD his-
ology was not confirmed [72,76,77,80], and the effects of met-
ormin on liver disease progression have been questioned [81].
Many more data are available with the peroxisome-
roliferator activator receptor-  (PPAR-) agonists (glitazones)
s insulin sensitizers (Table 2). They definitely reduce pro-
ression to diabetes in persons at risk, via enhanced insulin
ensitivity in skeletal muscles and in the liver as well as in
he adipose tissue, where they also promote adipocyte differ-
ntiation. The first evidence with glitazones on NAFLD was
roduced in 2001, a small pilot trial reported reduced serum
LT levels in 10 patients treated with troglitazone, but minor
r no effects on liver histology [82]. Nine cases were free of
iabetes, and troglitazone was highly effective in reducing pro-
ression from prediabetes to diabetes in a treatment arm inside
he Diabetes Prevention Program [83]. Troglitazone was later
ithdrawn from the market, but both rosiglitazone and piogli-
azone treatment in the early prediabetes phase have shown a
eneficial effect on diabetes risk prevention [84], and are the
ost extensive studied drugs on NASH treatment [73–75,78,79].
lso acarbose treatment reduces the risk of diabetes develop-
ent [85], but no data have been raised on histologic outcomes
f NAFLD and no effects have been demonstrated on hepatic
iochemistry.
a
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Other drugs have more recently entered the arena. The dual
PAR-/  agonist GFT-505 (Elafibranor®) showed potentially
seful results in a small pilot study in obesity, where it also
emonstrated an insulin-sensitizing activity [86]. GFT-505 has
ecently completed a phase IIb trial with positive results on
AFLD histology, and the publication of final results is eagerly
waited. Bile acids have been reported to regulate hepatic lipid
nd glucose metabolism through FXR, a member of the nuclear
ormone receptor superfamily, and TGR5, a G protein-coupled
ile acid receptor 1. Whereas no solid data are available for
 beneficial effect of ursodeoxycholic acid on histology in
ASH patients, obeticholic acid has recently been reported
o promote NASH remission in a phase II study [35]. How-
ver, no advantage on glucose metabolism was reported and
he use of this compound may be limited by some impor-
ant side effects (e.g., pruritus and increase in LDL-cholesterol
oncentrations).
The most interesting drugs for a potentially favourable effect
n both glucose and liver disease is the class of incretin mimet-
cs. The rationale for their use (both the glucagon-like peptide-1
eceptor agonists [GLP-1Ra] and the dipeptidyl peptidase-4
nhibitors [DPP-4i]) in NAFLD comes from a report of a
educed expression of GLP-1 receptors in the biopsies from
ASH patients, in comparison with control biopsies [87]. GLP-
Ra and DPP-4i are also likely to improve NAFLD through
mproved insulin sensitivity [88]. Initial studies in NASH were
arried out with the short-acting GLP-1Ra exenatide; in a pilot
tudy it produced a positive effect on liver histopathology in
hree out of 8 cases [89]. The long-acting GLP-1Ra liraglu-
ide has now completed a phase IIb trial, showing a significant
ositive effect on NASH remission, independent of the pres-
nce of diabetes [58]. The mechanism(s) might be mediated
y improved insulin sensitivity and reduced hepatic de  novo
ipogenesis [90].
At present, several phase II studies are being planned to mea-
ure the long-term effects of different GLP-1Ra in NAFLD,
aving the strictly defined histological outcome of NASH remis-
ion as primary outcome. Future studies should also compare the
elative effects of GLP-1Ra treatment in comparison to weight
oss programs in obese subjects, whereas drug treatment will
emain the treatment of choice in lean NAFLD [91].
.  Conclusions
In this updated review of the published studies, we provide
urther support for the strong association between NAFLD and
ncreased risk of new-onset type 2 diabetes, though causality
emains to be proven in well-controlled prospective and inter-
ention studies. Future studies are also needed to assess the
otential added value of using the presence of NAFLD to pre-
ict the risk of incident type 2 diabetes beyond that provided
y common risk factors for diabetes. Finally, in the presence
f NAFLD, therapeutic strategies should tackle both the risk of
dvanced liver disease and the risk of type 2 diabetes, in turn
esponsible for liver disease progression.
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